Diagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01446094|
Recruitment Status : Recruiting
First Posted : October 4, 2011
Last Update Posted : October 3, 2017
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease||Drug: regadenoson||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease|
|Study Start Date :||August 2011|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||June 2018|
Additional images collected during routine cardiac MRI (CMR) with diagnostic imaging agent, regadenoson.
Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
Other Name: Lexiscan
- Profile of sensitivity, specificity, and diagnostic accuracy of rapid regadenoson stress CMR. [ Time Frame: Up to 7 days ]Evaluate the profile of sensitivity, specificity, and diagnostic accuracy of a rapid regadenoson stress CMR protocol for the detection of >= 70% stenosis of a major epicardial coronary artery on invasive coronary angiography.
- Evaluate time for performance of rapid regadenoson stress CMR protocol. [ Time Frame: Up to 7 days ]Evaluate duration of time for performance of rapid regadenoson stress CMR protocol in comparison to time for performance of standard regadenoson stress CMR protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01446094
|Contact: Mohaman Ghosn, PhDfirstname.lastname@example.org|
|United States, Texas|
|The Methodist Hospital||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Ghosn Mohamad, PhD 713-441-9837 email@example.com|
|Principal Investigator: Dipan J Shah, MD|
|Sub-Investigator: Neal S Kleiman, MD|
|Sub-Investigator: Faisal Nabi, MD|
|Sub-Investigator: Kamran Shaikh, MD|
|Principal Investigator:||Dipan Shah, M.D.||The Methodist Hospital System|